{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0"},{"groupId":"OG001","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"MTD was defined as the highest dose at which 1 or fewer among 6 participants or less than or equal to (\\<=) 33 percent (%) experienced a dose-limiting toxicity (DLT) (calculated based on adjusted ideal body weight \\[AIBW\\]). AIBW was calculated as ideal body weight (IBW) + 0.4 \\* (actual weight - IBW), where IBW for men was 0.9 \\* height in centimeters (cm) - 88 and IBW for women was 0.9 \\* height in cm - 92. DLT was defined as a treatment-emergent adverse event (TEAE) or abnormal laboratory value related to study treatment (that is, assessed as unrelated to disease, intercurrent illness, or concomitant medications), including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment.","groups":[{"description":"Participants received mirvetuximab soravtansine IV infusion on Day 1 of every 21-day (Q3W) cycle. Dose escalation started at 0.15 mg/kg and proceeded through 7.0 mg/kg. Participants continued to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever came first, or until the sponsor terminated the study.","id":"OG000","title":"Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)"},{"description":"Participants received mirvetuximab soravtansine IV infusion on Days 1, 8, and 15 of every 28-day cycle. Dose escalation started at 1.1 mg/kg and proceeded through 2.5 mg/kg. Participants continued to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever came first, or until the sponsor terminated the study.","id":"OG001","title":"Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who were enrolled and received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (21 days)","title":"Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of Mirvetuximab Soravtansine","type":"PRIMARY","unitOfMeasure":"mg/kg"}